Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. (ARCT) is a clinical-stage RNA medicines company pioneering novel therapeutics and vaccines through its proprietary delivery platforms. This news hub provides investors and researchers with timely updates on the company's progress in developing self-amplifying mRNA (sa-mRNA) vaccines and rare disease treatments.
Access official press releases covering regulatory milestones, clinical trial developments, and strategic partnerships. Our curated collection includes updates on the LUNAR® delivery system's applications, STARR® mRNA technology advancements, and global collaborations like the ARCALIS joint venture in Japan.
Key updates include earnings reports, research publications, manufacturing expansions, and patent grants. Bookmark this page for direct access to primary source materials about ARCT's work in nucleic acid therapeutics, including programs targeting liver disorders, respiratory diseases, and infectious disease prevention.
For stakeholders tracking RNA medicine innovation, this repository offers organized chronological updates without promotional commentary. Check regularly for verified information about clinical-stage candidates and technology licensing agreements that demonstrate Arcturus' position in the biotechnology sector.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced it will release its financial results for the quarter ended March 31, 2023, after the market close on May 9, 2023. The Company, focused on mRNA medicines for infectious disease vaccines and rare diseases, will also host a conference call and webcast at 4:30 PM ET on the same day. Established in 2013 and based in San Diego, Arcturus utilizes innovative delivery technologies like LUNAR® and STARR™ mRNA Technology. Its pipeline includes candidates for treating ornithine transcarbamylase deficiency and cystic fibrosis, alongside partners in mRNA vaccine programs for COVID-19 and influenza. For more details, visit www.ArcturusRx.com.
Arcturus Therapeutics Holdings announced significant financial results for Q4 2022, highlighting a revenue surge to $160.3 million, driven by a $200 million payment from CSL collaboration. The company achieved $90 million in development milestones in March 2023, bolstering its cash runway into 2026. ARCT-154 Phase 3 trial for COVID-19 booster is fully enrolled in Japan, with ARCT-810 and ARCT-032 advancing in clinical trials. The company reported a net income of $117.3 million for Q4, compared to a loss the previous year. Cash balance was $391.9 million at year-end, reflecting a robust financial position.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) will release its financial results for the fourth quarter and full year ended December 31, 2022, after market close on March 28, 2023. A conference call will follow that day at 4:30 p.m. ET. Additionally, Arcturus will present at the Guggenheim Healthcare Talks: Genomic Medicines & Rare Disease Day on April 3, 2023, at 2:10 p.m. ET. Founded in 2013 and based in San Diego, Arcturus focuses on developing mRNA medicines and vaccines for infectious diseases and rare liver and respiratory diseases. The company employs LUNAR® lipid-mediated delivery and STARR™ mRNA Technology to support its diverse pipeline.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced its participation in two upcoming investor conferences. The SVB Securities Global Biopharma Conference will take place on
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced the approval of its Clinical Trial Application (CTA) for ARCT-032, an inhaled mRNA treatment for cystic fibrosis (CF). This marks the progression into Phase 1 First-in-Human studies in New Zealand. Joseph Payne, CEO, emphasized the potential of ARCT-032 to restore CFTR protein in CF patients, including those without effective treatment options. Preclinical data showcased robust CFTR expression in human bronchial epithelial cells. Cystic fibrosis, a serious genetic disorder, currently lacks effective treatments for many mutation types, making this development particularly significant.
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) announced its participation in the Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2023, at 9:00 a.m. Pacific Time. The company, known for its mRNA medicines and vaccines, will discuss its pipeline focused on vaccines for infectious diseases and treatments for rare liver and respiratory diseases. A webcast of the presentation will be available on the company's investor relations website.
Founded in 2013, Arcturus continues to innovate in RNA therapeutics with extensive patent coverage.
FAQ
What is the current stock price of Arcturus Therape (ARCT)?
What is the market cap of Arcturus Therape (ARCT)?
